Table 3.

Molecular characteristics of the “Phase II–eligible” patients: The specific molecular profile of 25 patients with advanced solid tumors who received entrectinib on either phase I trial (ALKA-372-001 or STARTRK-1) is summarized

NumberGeneTumor typeMolecular alterationDiagnostic method
1NTRKNSCLCSQSTM1–NTRK1NGS
2NTRKGlioneuronalBCAN–NTRK1NGS
3NTRKMASCETV6–NTRK3NGS
4NTRKmCRCLMNA–NTRK1NGS
5ROS1NSCLCROS1+FISH
6ROS1NSCLCROS1+FISH
7ROS1NSCLCCD74–ROS1NGS
8ROS1NSCLCROS1+FISH
9ROS1NSCLCROS1+FISH
10ROS1NSCLCEZR–ROS1NGS
11ROS1NSCLCROS1+FISH
12ROS1MelanomaGOPC–ROS1NGS
13ROS1NSCLCROS1+FISH
14ROS1NSCLCROS1+FISH
15ROS1NSCLCROS1+FISH
16ROS1NSCLCROS1+FISH
17ROS1NSCLCROS1+FISH
18ROS1NSCLCSDC4–ROS1NGS
19ALKNSCLCALK+FISH
20ALKNSCLCALK+FISH
21ALKRCCVCL–ALKNGS
22ALKNSCLCALK+FISH
23ALKmCRCCAD–ALKNGS
24ALKNSCLCALK+FISH
25ALKUnknown primaryD5F3–ALKNGS
  • Abbreviations: mCRC, metastatic colorectal cancer; NGS, next-generation sequencing; RCC, renal cell carcinoma.